PubMedCrossRef 4 Lang L: FDA approves use of bacteriophages to b

PubMedCrossRef 4. Lang L: FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 2006, 131:1370–1372.Quisinostat concentration PubMed 5. William Summers C: Bacteriophage therapy. Annu Rev Microbiol 2001, 55:437–451.CrossRef

6. Young R: Bacteriophage lysis: mechanism and regulation. Microbiol Rev 1992, 56:430–81.PubMed 7. Young RJ: Bacteriophage holins: deadly diversity. Mol Microbiol Biotechnol 2002, 4:21–36. 8. Loessner MJ: Bacteriophage endolysins – current state of research and applications. Current Opinion in Microbiology 2005, 8:480–487.PubMedCrossRef GS-1101 in vivo 9. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S: Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci 1996, 93:3188–3192.PubMedCrossRef 10. Projan S: Phage-inspired

antibiotics? check details Nat Biotechnol 2004, 22:185–91.CrossRef 11. Padmanabhan S, Sriram B, Sagar P, Shashikala V, Ramachandran J: Insertional inactivation of the T4 lysozyme gene: Model for absolute lysis-defectives in phage therapy. ASM Conference on the New Phage Biology: the ‘Phage Summit’:1–5 Aug 2004; Key Biscayne, Florida, USA 12. Ramachandran J, Sriram P, Sriram B: Lysin deficient bacteriophages having reduced immunogenecity. US Patent No; 6,896,882 13. Hagens S, Bläsi U: Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 2003, 37:318–323.PubMedCrossRef 14. Hagens S, Habel A, von Ahsen U, von Gabain A, Bläsi U: Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 2004, 48:3817–3822.PubMedCrossRef 15. Lu TK, Collins JJ: Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci 2007, 104:11197–11202.PubMedCrossRef

Levetiracetam 16. Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M, Stapleton PP, Daly JM: Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 2005, 137:639–646.PubMedCrossRef 17. Hiramatsu K, Katayama Y, Yuzawa H, Ito T: Molecular genetics of methicillin-resistant Staphylococcus aureus. Int J Med Microbiol 2002, 292:67–74.PubMedCrossRef 18. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999, 340:493–501.PubMedCrossRef 19. CDC: Staphylococcus aureus Resistant to Vancomycin – United States 2002. MMWR 2002, 51:565–567. 20. Perl TM, Golub JE: New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S. aureus nasal carriage. Ann Pharmacother 1998, 32:S7–16.PubMed 21.

Comments are closed.